Tim Kutzkey Buys 5,523 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey bought 5,523 shares of Surrozen stock in a transaction that occurred on Wednesday, January 14th. The stock was bought at an average cost of $19.99 per share, for a total transaction of $110,404.77. Following the purchase, the director owned 999,429 shares in the company, valued at $19,978,585.71. This represents a 0.56% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Tim Kutzkey also recently made the following trade(s):

• On Tuesday, January 13th, Tim Kutzkey purchased 12,470 shares of Surrozen stock. The shares were bought at an average cost of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey purchased 15,100 shares of Surrozen stock. The stock was bought at an average cost of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The stock was bought at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey acquired 5,266 shares of Surrozen stock. The shares were bought at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey acquired 315,457 shares of Surrozen stock. The shares were bought at an average price of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Performance

Shares of SRZN stock opened at $20.00 on Friday. The firm has a 50-day moving average price of $18.70 and a 200 day moving average price of $13.92. Surrozen, Inc. has a twelve month low of $5.90 and a twelve month high of $24.94. The company has a market capitalization of $171.40 million, a price-to-earnings ratio of -0.90 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The firm had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. As a group, research analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Institutional Investors Weigh In On Surrozen

A number of institutional investors have recently added to or reduced their stakes in the company. Woodline Partners LP acquired a new stake in Surrozen during the third quarter worth about $621,000. Millennium Management LLC acquired a new position in shares of Surrozen in the 3rd quarter valued at about $1,414,000. Citadel Advisors LLC grew its holdings in shares of Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the period. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Surrozen during the 3rd quarter worth about $889,000. Finally, Acuta Capital Partners LLC increased its position in Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after purchasing an additional 8,415 shares in the last quarter. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Lifesci Capital raised Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.